Leiomyoma
Also known as: Fibroid, Leiomyoma, Fibrous, Tumor
Methodology & AI Transparency ⓘ
Leiomyoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Leiomyoma (also termed Fibroid or Leiomyoma) (D25.9; PCOS, Endometriosis & Gynecologic Health) utilize iron repletion [Leiomyoma D25.9] and objective CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)) targets (Ferritin > 50 ng/mL (D25.9)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to PCOS, Endometriosis & Gynecologic Health under ICD-10-CM D25.9 for Leiomyoma clinical workups.
- 3 Typical cash cost range: Workup highlights for Leiomyoma (D25.9): iron repletion [Leiomyoma D25.9].
- 4 Top reported side effects / signs: Key OB/GYN & PCOS biomarkers for Leiomyoma (D25.9): CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)) & LH, FSH & in Leiomyoma (D25.9: Prolactin) (Normal ovulatory endocrine axis (D25.9)).
Ask our AI Specialists anything about Leiomyoma
What Is Leiomyoma?
Physicians managing Leiomyoma (also termed Fibroid or Leiomyoma) (D25.9; PCOS, Endometriosis & Gynecologic Health) utilize iron repletion [Leiomyoma D25.9] and objective CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)) targets (Ferritin > 50 ng/mL (D25.9)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Leiomyoma (D25.9, OB/GYN & PCOS) reflects or estrogen-dependent ectopic in Leiomyoma (D25.9: endometrial inflammation). longitudinal control is benchmarked via CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)).
Common Symptoms & Clinical Signs
- • Presentation of Leiomyoma (D25.9): hyperandrogenic acne along in Leiomyoma (D25.9: the jawline, hirsutism,)
- • Secondary Leiomyoma clinical sign: pelvic pressure, bloating, in Leiomyoma (D25.9: or pain radiating)
- • Symptom flares in Leiomyoma correlating with CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)) deviation outside Ferritin > 50 ng/mL (D25.9)
- • Functional ob/gyn & pcos impact requiring iron repletion [Leiomyoma D25.9] evaluation (D25.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Leiomyoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D25.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CBC & Serum in Leiomyoma (D25.9: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (D25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LH, FSH & in Leiomyoma (D25.9: Prolactin) | Normal ovulatory endocrine axis (D25.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free & Total in Leiomyoma (D25.9: Testosterone + SHBG) | Sex-specific physiological range (D25.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Leiomyoma
Treatment selection for Leiomyoma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Leiomyoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary: What a 1,012-Participant Study Found This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. BJOG : an international journal of obstetrics and gynaecology • 2025-08-15 • Phase III Randomized Trial | N = 1,012 | 96/100 | PMID 40326221 ↗ |
| New Insights on Relugolix combination therapy in European women with symptomatic uterine: What a 388-Participant Study Found In European women with UF and HMB, once-daily relugolix-CT vs. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2023-08-17 • Phase III Randomized Trial | N = 388 | 93/100 | PMID 37634528 ↗ |
| Can This Approach Help? Inside the Latest Research on Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With The author describes the results of a study to examine the effect of three treatment regimens on pain associated with endometriosis. Journal of obstetric, gynecologic, and neonatal nursing : JOGNN • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39395815 ↗ |
| Can This Approach Help? Inside the Latest Research on Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. Obstetrics and gynecology • 2022-06-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35675604 ↗ |
| Can This Approach Help? Inside the Latest Research on Ulipristal acetate compared with leuprorelin acetate for Japanese women with No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group. Fertility and sterility • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33715871 ↗ |
Leiomyoma Patient Community & “People Like Me” Threads
Filter Leiomyoma community threads and patient logs by age, biological sex, dosage, and treatment duration.